Watkins Dean E, Craig Daniel J, Vellani Shahnaz D, Hegazi Ahmad, Fredrickson Kaylee J, Walter Adam, Stanbery Laura, Nemunaitis John
University of Toledo Medical Center, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
ProMedica Toledo Hospital, Toledo, OH 43606, USA.
J Clin Med. 2023 Sep 15;12(18):5992. doi: 10.3390/jcm12185992.
Cervical cancer is an international public health crisis, affecting several hundred thousand women annually. While not universally protective due to other risk factors, many such cases are preventable with vaccination against high-risk serotypes of the human papilloma virus (HPV 6, 11, 16, 18, 31, 33, 45, 53, 58). Advanced-stage and recurrent cervical cancers are typically lethal and have been the focus in recent years of the integration of immune checkpoint inhibitors (CPIs) to improve survival. We have consolidated information regarding the role of the immune system in both disease progression and disease clearance with the aid of targeted therapies and immunotherapeutic agents. Additionally, we have characterized the treatment modalities currently indicated as the standard of care-such as bevacizumab and the immune CPIs-and those recently approved or in development, including Tivdak, Vigil, and chimeric antigen receptor (CAR) T-cells.
宫颈癌是一场国际公共卫生危机，每年影响着数十万女性。虽然由于其他风险因素，疫苗并非对所有人都有保护作用，但许多此类病例可通过接种针对高危血清型人乳头瘤病毒（HPV 6、11、16、18、31、33、45、53、58）的疫苗来预防。晚期和复发性宫颈癌通常是致命的，近年来一直是免疫检查点抑制剂（CPI）整合以提高生存率的重点。我们借助靶向治疗和免疫治疗药物整合了有关免疫系统在疾病进展和疾病清除中作用的信息。此外，我们还描述了目前被视为标准治疗方案的治疗方式，如贝伐单抗和免疫CPI，以及最近获批或正在研发的治疗方式，包括Tivdak、Vigil和嵌合抗原受体（CAR）T细胞。
